Responses
Rheumatoid arthritis
Original research
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study
Compose a Response to This Article
Other responses
No responses have been published for this article.